期刊
ONCOLOGIST
卷 17, 期 2, 页码 267-273出版社
WILEY
DOI: 10.1634/theoncologist.2011-0219
关键词
Early palliative care; Efficacy of palliative care; Symptom control; Cost of care; Quality care; Supportive care
类别
资金
- Ameritox
- Archimedes Pharmaceuticals
- Boston Scientific
- Covidien Mallinckrodt Inc.
- Endo Pharmaceuticals
- Forest Labs
- K-Pax Pharmaceuticals
- Meda Pharmaceuticals
- Medtronics
- Otsuka Pharma
- ProStrakan
- Purdue Pharma
- Salix
- St. Jude Medical
- Pfizer
- Lilly
- Bristol-Myers Squibb
- KangLaiTe
- Alexion
- Biovex
- DARA
- MiCo
- NIH
- Robert Wood Johnson Foundation
- AHRQ
- Amgen
- Helsinn Therapeutics
- Novartis
- National Institutes of Health through MD Anderson's Cancer Center [CA016672]
Cancer patients develop severe physical and psychological symptoms as a result of their disease and treatment. Their families commonly suffer great emotional distress as a result of caregiving. Early palliative care access can improve symptom control and quality of life and reduce the cost of care. Preliminary results show that early palliative care access can also extend survival. Unfortunately, only a minority of cancer centers in the U.S. have the two most important resources for palliative care delivery: outpatient palliative care centers and inpatient palliative care units. In this article, we use a case presentation to discuss the impact of early palliative care access in light of the currently available evidence, and we recommend ways to improve early access to palliative care through education and research. The Oncologist 2012;17:267-273
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据